76 related articles for article (PubMed ID: 38302968)
1. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
Liao L; Tang J; Hong Z; Jiang W; Li Y; Kong L; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Yu J; Yang W; Pan Z; Ding PR
BMC Cancer; 2024 Feb; 24(1):164. PubMed ID: 38302968
[TBL] [Abstract][Full Text] [Related]
2. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Strategies for Locally Advanced Colon Cancer.
Nair KG; Kamath SD; Chowattukunnel N; Krishnamurthi SS
Curr Treat Options Oncol; 2024 Mar; 25(3):376-388. PubMed ID: 38349502
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D; Kalaitzaki E; Church DN; Pandha H; Tomlinson I; Annels N; Gerlinger M; Sclafani F; Smith G; Begum R; Crux R; Gillbanks A; Wordsworth S; Chau I; Starling N; Cunningham D; Dhillon T
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079623
[TBL] [Abstract][Full Text] [Related]
5. The depth of perineural invasion is an independent prognostic factor for stage II colorectal cancer.
Chen H; Wang C; Chen Z; Huang T; Lin Y; Chen J; Zhang B; He X
BMC Cancer; 2024 Apr; 24(1):433. PubMed ID: 38589842
[TBL] [Abstract][Full Text] [Related]
6. High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.
Mohamed A; Jiang R; Philip PA; Diab M; Behera M; Wu C; Alese O; Shaib WL; Gaines TM; Balch GG; El-Rayes BF; Akce M
Front Oncol; 2021; 11():755113. PubMed ID: 34760701
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive significance of perineural invasion in stage I to III colon cancer: a propensity score matching-based analysis.
Chu CH; Lai IL; Jong BK; Chiang SF; Tsai WS; Hsieh PS; Yeh CY; You JF
World J Surg Oncol; 2024 May; 22(1):129. PubMed ID: 38734718
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
9. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
[TBL] [Abstract][Full Text] [Related]
10. Making sense of adjuvant chemotherapy in colorectal cancer.
Chan GHJ; Chee CE
J Gastrointest Oncol; 2019 Dec; 10(6):1183-1192. PubMed ID: 31949938
[TBL] [Abstract][Full Text] [Related]
11. Challenges in the management of stage II colon cancer.
Dotan E; Cohen SJ
Semin Oncol; 2011 Aug; 38(4):511-20. PubMed ID: 21810510
[TBL] [Abstract][Full Text] [Related]
12. Real-life experiences and barriers to adjuvant chemotherapy in Saudi patients with advanced stage II and stage III colon cancer.
Alyabsi MS; Alqarni AH; Almutairi AF; Alselaim NA; Algarni MA; Alshammari KM
Saudi J Gastroenterol; 2024 Mar; 30(2):114-122. PubMed ID: 37955212
[TBL] [Abstract][Full Text] [Related]
13. What We Know About Stage II and III Colon Cancer: It's Still Not Enough.
Puccini A; Berger MD; Zhang W; Lenz HJ
Target Oncol; 2017 Jun; 12(3):265-275. PubMed ID: 28504299
[TBL] [Abstract][Full Text] [Related]
14. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
Wu C; Pai RK; Kosiorek H; Banerjee I; Pfeiffer A; Hagen CE; Hartley CP; Graham RP; Sonbol MB; Bekaii-Saab T; Xie H; Sinicrope FA; Patel B; Westerling-Bui T; Shivji S; Conner J; Swallow C; Savage P; Cyr DP; Kirsch R; Pai RK
Clin Cancer Res; 2024 May; 30(9):1811-1821. PubMed ID: 38421684
[TBL] [Abstract][Full Text] [Related]
15. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM
J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence.
Piercey O; Wong HL; Leung C; To YH; Heong V; Lee M; Tie J; Steel M; Yeung JM; McCormick J; Gibbs P; Wong R
Clin Colorectal Cancer; 2024 Mar; 23(1):95-103.e3. PubMed ID: 38242766
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors associated with relapse of stage II/III colon cancer treated with peroral anti-cancer agents in the adjuvant setting.
Mizuuchi Y; Tanabe Y; Sada M; Kitaura Y; Nagai S; Watanabe Y; Tamiya S; Nagayoshi K; Ohuchida K; Nakano T; Nakamura M
Mol Clin Oncol; 2021 Jun; 14(6):122. PubMed ID: 33936595
[TBL] [Abstract][Full Text] [Related]
18. Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer.
Peixoto RD; Kumar A; Lim HJ
J Gastrointest Oncol; 2015 Oct; 6(5):487-91. PubMed ID: 26487941
[TBL] [Abstract][Full Text] [Related]
19. The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study.
Kim YW; Choi EH; Kim BR; Ko WA; Do YM; Kim IY
Oncotarget; 2017 Oct; 8(45):80061-80072. PubMed ID: 29108388
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis serves as an important pathological characteristic of stage I-II colon cancer.
Dong S; Xu J; Li M; Xiong G; Wang R
Indian J Pathol Microbiol; 2024 May; ():. PubMed ID: 38727689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
